WOODCLIFF LAKE, N.J., May 9, 2013 /PRNewswire/ -- Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The donation, which is being disbursed in four yearly installments of $250,000, will support the Conquer Cancer Foundation Mission Endowment, which was established to provide a long-term base of support to advance the Foundation's critical mission to improve the care and treatment of people living with cancer. The Mission Endowment focuses on funding research, professional education, patient education and information, international programs and initiatives that aim to improve access to and quality of care.
"Eisai USA Foundation is committed to advancing knowledge, research and patient care, particularly in oncology, a long-standing area of focus for Eisai," said Hideo Dan, executive vice president of the Eisai USA Foundation. "The work of the Conquer Cancer Foundation and ASCO aligns with our human health care (hhc) mission to help make a difference in the lives of patients. We are proud to support their vision of a world free from the fear of cancer."
"Eisai has been a dedicated supporter of the Conquer Cancer Foundation, providing critical funding for a range of initiatives over the years," said W. Charles Penley, MD, FASCO, Chair of the Conquer Cancer Foundation Board of Directors. "With Eisai's generous contribution to the Foundation's Mission Endowment, we can further expand our efforts to conquer cancer worldwide by funding breakthrough cancer research and sharing cutting-edge knowledge."
Eisai USA Foundation Inc.
The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's commitment to be a responsible corporate citizen and contribute to the good of the society in which it does business. The Foundation focuses its charitable giving in four areas: health-related initiatives for patients and caregivers, disaster relief efforts, innovation in medical and pharmaceutical sciences, and community activities in the areas where Eisai's U.S. employees live and work.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
SOURCE Eisai Inc.
Type Press Release
Date Released May 09, 2013